Complications of Autologous Lymph-node Transplantation for Limb Lymphoedema  by Vignes, S. et al.
Complications of Autologous Lymph-node Transplantation for Limb
Lymphoedema
S. Vignes *, M. Blanchard, A. Yannoutsos, M. Arrault
Department of Lymphology, Centre National de Référence des Maladies Vasculaires Rares (lymphœdèmes primaires), Hôpital Cognacq-Jay, 15, rue Eugène Millon,
75015 Paris, France* Cor
Cognac
81 35;
E-ma
1078
Surgery
http:WHAT THIS PAPER ADDS
This report concerns the complications arising after autologous lymph-node transplantation to treat primary or
secondary upper- or lower-limb lymphoedema, including persistent iatrogenic lymphoedema of the limb cor-
responding to the donor-node site. Patients must be made aware of the potential risk of grafting before
undergoing surgery.Objective: This study aims to assess potential complications of autologous lymph-node transplantation (ALNT) to
treat limb lymphoedema.
Design: Prospective, observational study.
Method: All limb-lymphoedema patients, followed up in a single lymphology department, who decided to
undergo ALNT (January 2004eJune 2012) independently of our medical team, were included.
Results: Among the 26 patients (22 females, four males) included, 14 had secondary upper-limb lymphoedema
after breast-cancer treatment and seven had secondary and ﬁve primary lower-limb lymphoedema. Median
(interquartile range, IQR) ages at primary lower-limb lymphoedema and secondary lymphoedema onset were
18.5 (13e30) and 47.4 (35e58) years, respectively. Median body mass index (BMI) was 25.9 (22.9e29.3) kg m2.
For all patients, median pre-surgery lymphoedema duration was 37 (24e90) months. Thirty-four ALNs were
transplanted into the 26 patients, combined with liposuction in four lower-limb-lymphoedema patients. Ten
(38%) patients developed 15 complications: six, chronic lymphoedema (four upper limb, two lower limb), deﬁned
as 2-cm difference versus the contralateral side, in the limb on the donor lymph-node-site territory, persisting
for a median of 40 months post-ALNT; four, post-surgical lymphocoeles; one testicular hydrocoele requiring
surgery; and four with persistent donor-site pain. Median (IQR) pre- and post-surgical lymphoedema volumes,
calculated using the formula for a truncated cone, were, respectively, 1023 (633e1375) ml (median: 3 (1e6)
months) and 1058 (666e1506) ml (median: 40 (14e72) months; P ¼ 0.73).
Conclusion: ALNT may engender severe, chronic complications, particularly persistent iatrogenic lymphoedema.
Further investigations are required to evaluate and clearly determine its indications.
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
Article history: Received 11 August 2012, Accepted 22 November 2012, Available online 8 January 2013
Keywords: Complication, Lymphoedema, Autologous lymph-node transplantation, SurgeryLymphoedema is a chronic and often debilitating disorder
caused by lymphatic insufﬁciency. It can be either primary
or secondary, mainly after cancer treatment including
surgery and/or radiotherapy. Lymphoedema management is
based upon complete decongestive physiotherapy and is
divided into two phases: the ﬁrst, to reduce lymphoedema
volume, and the second, to maintain the reduced volume.
It includes multilayer low-stretch bandages to diminish
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//dx.doi.org/10.1016/j.ejvs.2012.11.026followed by the wearing of elastic garments to stabilise the
volume.1,2
Surgical treatment of lymphoedema has been advocated
as an alternative or adjunctive technique with the aim of
‘curing’ the disease. Several categories of surgical procedures
have been proposed to treat lymphoedema, including exci-
sional procedures (after intensive complete physiotherapy
and cutaneous resection to remove excess limb ﬂaps or
lymphoedematous genital skin), liposuction, lymphatic
reconstructions (lymphovenous anastomosis and lymphatic
channel graft) and tissue-transfer procedures (autologous
lymph-node transplantation (ALNT) and autologous stem-cell
transplantation).3 Complications of the surgery are rarely
mentioned in articles. Among the different types of surgery,
ALNT, essentially proposed to treat patients with cancer-
related or primary lymphoedema, can be responsible for
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we analysed the complications arising in patients whose limb
lymphoedema was treated with ALNT.
PATIENTS AND METHODS
Subjects
All patients with primary or secondary limb lymphoedema,
who had undergone ALNT between January 2005 and June
2012 and were included in this observational study, were
followed up prospectively for their initial lymphoedema and
the evaluation of the limb corresponding to the donor site
in our centre specialised in lymphoedema management;
they continue to be followed up prospectively. Our centre
manages lymphoedema diagnosis, its medical treatment,
that is, intensive decongestive physiotherapy, educational
and counselling measures, adapted physical activities and
long-term follow-up during the maintenance phase but not
surgery. All patients made the decision to undergo ALNT
with the hope of ‘curing’ their disease and thereby avoiding
the constraining long-term compression therapy. Our
medical team was not implicated in this decision.
Iatrogenic lymphoedema was clinically diagnosed as
increased limb volume with 2-cm difference compared to
the contralateral non-lymphoedematous limb, as used for
upper-limb lymphoedema after breast-cancer treatment.8
For the lower limb, the clinical diagnosis was conﬁrmed by
the thickening of the skin of the dorsal side of the foot
(KaposieStemmer sign).Data collected
The following information was recorded: patient charac-
teristics, body mass index (BMI ¼ BW (kg)/H2 (m2), where
BW is body weight and H height) at the time of the ﬁrst
examination and lymphoedema characteristics (date of
onset and duration, lymphoedema volume at inclusion,
primary or secondary, past cellulitis (erysipelas)). Breast-
cancer treatment included mastectomy (n ¼ 7) or
tumourectomy (n ¼ 7) with axillary lymph-node dissection
and radiotherapy (n ¼ 14) and chemotherapy (n ¼ 12).
Secondary lower-limb lymphoedema was associated with
cervical cancer treatment, including radical hysterectomy
with pelvic lymphadenectomy and brachytherapy (n ¼ 4),
endometrial cancer (n ¼ 1) and testicular cancer or inguinal
hamartoma, one each.
Speciﬁc lymphoedema treatments were also recorded
(multilayer low-stretch bandage, manual lymph drainage
and elastic garment).Lymphoedema volume
The volume of the lymphoedema was calculated for each
5-cm segment using the formula for a truncated cone:
H  (C2 þ Cc þ c2)/12p, where H is height and C and c the
circumferences of the top and base of the cone, respectively.9
The ‘0’ starting point for the measurement was the elbow
fold for the upper limb and the lower edge of the patella for
the lower limb. Limb circumferences were measured every5 cm: for the upper limb, 20 cm from 0 to the wrist and 15 cm
from 0 to the shoulder and for lower limb, 30e35 cm from
0 to the ankle and 25e30 cm from 0 to the hip.
This method has demonstrated excellent inter- and intra-
observer reproducibilities for lower and upper limbs, when
compared to water displacement, which remains the gold
standard.10,11 Lymphoedema volume was deﬁned as the
difference between the lymphoedematous limb volume and
that of the healthy limb before and after ALNT.
ALNT
The technical procedure has been described previously.6,7
Brieﬂy, the axillary or inguinal donor-site area was meticu-
lously dissected. Lymph nodes were harvested with an
abundant amount of surrounding fat and were then trans-
planted into the axillary or inguinal receiving site of the
lymphoedematous limb. Artery and vein were anastomosed
with the previously prepared vessels, using microsurgical
techniques. Both axillary and inguinal approaches were
closed on suction drainage.
Statistical analyses
Results are expressed as medians (interquartile range, IQR)
or n (%). Paired Student’s t-test was used for comparisons.
P < 0.05 deﬁned signiﬁcance.
RESULTS
Twenty-six patients (22 females, four males) were included:
14 with secondary upper-limb lymphoedema, seven with
secondary lower-limb and ﬁve with primary lower-limb
lymphoedema. At the ﬁrst examination, median BMI was
25.9 (IQR: 22.9e29.3) kg m2. Median age at onset of
primary lower-limb lymphoedema and secondary lym-
phoedema were 18.5 (IQR: 13e30) and 47.4 (IQR: 35e58)
years, respectively. For all the patients, median lymphoe-
dema duration before surgery was 37 (IQR: 24e90) months.
Thirty-four ALNs were engrafted into the 26 patients and
combined with liposuction for four patients with lower-limb
lymphoedema (three secondary, one primary).
Complications
Table 1 lists the 15 complications that occurred post
transplantation in 10 (38%) patients, including persistent
lymphoedema that appeared during the ﬁrst year in the
limb corresponding to the donor lymph-node site (n ¼ 6:
four upper limb, two lower limb) and persisted for a median
of 40 months post ALNT (see Fig. 1), lymphocoele (n ¼ 4,
requiring one or more punctures), testicular hydrocoele
(n ¼ 1, requiring surgery) and persistent donor-site pain
(n ¼ 4). One patient developed postoperative staphylo-
coccal spondylodiscitis, considered a nosocomial infection,
successfully treated with prolonged antibiotic therapy.
Lymphoedema volume and its management
Median (IQR) lymphoedema volumes were 1023 (633e
1375) ml before ALNT (median: 3 (1e6) months) and 1058
Table 1. Characteristics of lymphoedema and complications after ALNT according to order and limb.
Patient Sex, age Lymphoedema Pregraft
duration (mo)
Donor-site, side Complications
Aetiology, side
Secondary
Upper limb Breast cancer
1 F, 52 Left 36 Inguinal, right Lymphoedema right lower limb,
donor-site pain
2 F, 42 Right 80 Inguinal, left
3 F, 64 Left 96 Inguinal, right
4 F, 68 Right 125 Inguinal, right & left
5 F, 63 Right 33 Inguinal, left Donor-site pain, lymphocele
6 F, 80 Left 86 Inguinal, right
7 F, 69 Right 28 Inguinal, left Donor-site pain, lymphocele
8 F, 68 Left 7 Inguinal, right
9 F, 48 Left 17 Inguinal, right & left
10 F, 67 Right 212 Inguinal, right Lymphocele
11 F, 36 Left 39 Inguinal, right Lymphoedema right lower limb
12 F, 48 Left 105 Inguinal, right
13 F, 59 Left 28 Inguinal, right
14 F, 49 Left 23 Inguinal, right
Lower limb
15 F, 46 Cervical cancer, right 29 Axillary, left
16 F, 46 Cervical cancer, left 16 Axillary, right & left;
inguinal, right
17 F, 33 Endometrial cancer, left 15 Axillary, left Lymphocele
18 F, 31 Cervical cancer, right 67 Axillary, right & left
19 M, 35 Inguinal hamartoma, left 49 Axillary, left; inguinal, right Lymphoedema left upper limb,
hydrocoele
20 M, 42 Testicular cancer, right 182 Axillary, left Lymphoedema, left upper limb,
donor-site pain
21 F, 63 Cervical cancer, left 31 Axillary left
Primary lower limb
22 M, 47 Right 178 Axillary, right & left
23 F, 10 Right 37 Axillary, left
24 F, 20 Left 20 Inguinal, right
25 F, 30 Right 2 Axillary, right Lymphoedema right upper limb
26 M, 21 Right 91 Axillary, right; inguinal left Lymphoedema right upper limb
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P ¼ 0.73). After a median 40 months of follow-up post
ALNT, treatment of the initial lymphoedema included self-
applied bandages (after learning from a specialised phys-
iotherapist) for 24 (92%), manual lymph drainage for 25
(96%) and an elastic garment for all patients. For the upper
limb, the elastic garment was always 20e36 mmHg, and, for
the lower limb, one (n ¼ 2) or two superposed (n ¼ 6), or
superposed 20e36 mm Hg and >36 mm Hg (n ¼ 4).
Iatrogenic lymphoedema was treated like the initial lym-
phoedema, with low-stretch bandages, an elastic garment
and, sometimes, manual lymph drainage.
DISCUSSION
This is the ﬁrst report devoted to complications that arose
after ALNT (n ¼ 15) to treat primary or secondary limb
lymphoedema in 10 patients. Some of them were transi-
tory, such as lymphocoele and hydrocoele, which were
cured by puncture or surgery. Others that persisted were
irreversible, such as iatrogenic lymphoedema on the donor-
site side, and chronic pain localised in the region of thesuperﬁcial femoral nerve, as previously described in 13
patients.12 Iatrogenic lymphoedema becomes a chronic
disease with its own complications, for example, worsening
or cellulitis. Iatrogenic secondary lymphoedema required
a speciﬁc therapeutic regimen with low-stretch bandages,
compression therapy and, sometimes, manual lymph
drainage. In previous retrospective studies on humans,
ALNT seemed to attenuate upper-limb cancer-related lym-
phoedema resistant to complete decongestive physio-
therapy or post-mastectomy chronic pain in women treated
for breast cancer.4,5 In those studies, lymphoedema volume
was not objectively quantiﬁed (volumetry) and no compli-
cations were reported. In addition, resistance to physio-
therapy is not a term clearly deﬁned in the literature. It
should be noted that our patients decided to undergo ALNT
to treat their lymphoedema, with the hope of curing it and
stopping compression therapy, without informing or
consulting our medical team.
Only 15e20% of women develop lymphoedema after
breast-cancer treatment including axillary lymph-node
dissection and only 3.5e7% after sentinel node biopsy.13e16
Figure 1. Patient 25, a 30-year-old woman, developed iatrogenic lymphoedema of the right hand after ALNT from the right axillary donor
site to the right inguinal site to treat primary lower-limb lymphoedema.
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axillary lymph nodes resected, external radiotherapy and
obesity.13,14 As suggested by Newman et al., patients
suffering from lymphoedema after cancer therapy probably
have predisposing factors, partially genetic, which might
contribute to increasing the risk of lymphoedema subse-
quent to treatment inducing lymphatic lesions.17 Moreover,
lymphatic function explorations in the contralateral limbs of
patients with primary lymphoedema showed abnormalities
indicating impaired lymphatic function.18 Those ﬁndings
might suggest more diffuse lymphatic insufﬁciency not
localised only to the lymphoedematous limb territory.
Moreover, near-infrared ﬂuorescent imaging of lymphatic
function in the contralateral normal limb of patients with
secondary upper-limb lymphoedema showed lymphatic
abnormalities in the affected and non-lymphoedematous
limbs.19 Considering more extensive and diffuse lymphatic
insufﬁciency and genetic predisposition, ALNT might create
a lymphatic function imbalance in these patients, leading to
lymphoedema onset in the donor-site side.
The absence of lymphoedema-volume regression in
humans might be explained by the accumulation of
adipose tissue and ﬁbrosis, mostly chronic and irrevers-
ible, secondary to lymph stasis, as demonstrated in
a mouse lymphoedema model.20,21 Moreover, the poor
efﬁcacy of ALNT might result from the unsustained anas-
tomoses between the graft and existing lymphatic vessels,
necessary for transplanted lymph-node function.22
Notably, in animal models (mouse and pig), damaged
lymphatic networks were repaired with ALNT combined
with growth factor therapy (vascular endothelial growth
factor (VEGF-C, D)).23,24The main strength of this study is that it was conducted
in a single centre specialised in lymphology. Lymphoe-
dema volume was measured precisely before and after
ALNT with a validated and reproducible method. Patients
were systematically asked about possible symptoms in the
limb corresponding to the lymph-node donor site.
However, our study has some limitations. The patients
included in this observational study made the decision to
undergo ALNT, without informing or consulting our
medical team. Moreover, we included all the patients who
underwent ALNT and are followed up in our Department
of Lymphology, but they represent only a small percentage
of the 1500 of patients who underwent this type of
surgery.6
ALNT is proposed to treat primary and secondary limb
lymphoedema. Patients must be alerted to the potential
risk of this intervention with various potential complica-
tions that are, in part, chronic and irreversible, such as
secondary lymphoedema in the donor-site limb. In our
small study, ALNT failed to attenuate secondary or primary
limb lymphoedema. Future prospective studies are
needed to determine accurately the indications for
and the long-term outcomes of ALNT in lymphoedema
management.FUNDING
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